ClinicalTrials.gg

Program

vonsetamig

Also written as “Vonsetamig” and “REGN5459”.

Its studies are mostly in Lupus Nephritis · Renal Insufficiency, Chronic · Multiple Myeloma, led by Regeneron Pharmaceuticals.

Furthest: phase 2, since Aug 29, 20193 company-led studies, 2 open or runningNext primary completion: Nov 22, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals32 open or runningphase 2since Aug 29, 2019Aug 29, 2019Nov 22, 2027phase 2 · NCT05092347

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 29, 2019First study: phase 2 study in Multiple MyelomaFirst studyNCT04083534 · 43 enrolled · United States
  2. Oct 22, 2021Phase 2 study in Renal Insufficiency, ChronicNCT05092347 · 43 enrolled · United States
  3. May 8, 2025Phase 1 study in Lupus NephritisNCT06975787 · 90 planned · United States, France, Germany and more

Ahead

  1. Nov 22, 2027Primary completion: phase 2 study in Renal Insufficiency, ChronicNCT05092347
  2. Sep 10, 2029Primary completion: phase 1 study in Lupus NephritisNCT06975787

TargetBeta

“A human bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the T-cell surface antigen CD3, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 37
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
cizutamigruleUCBphase 25
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rulekelonia-therapeutics-incphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06975787Lupus Nephritis · United States, France, Germany and more1RecruitingSep 10, 202990
NCT05092347Renal Insufficiency, Chronic · United States2Active, not recruitingNov 22, 202743
NCT04083534Multiple Myeloma · United States2CompletedMay 1, 202543

How it is read

Names in the registry

  • “Vonsetamig”, 2 entries
  • “REGN5459”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.